These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 234295)

  • 41. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
    Berd D; Maguire HC; McCue P; Mastrangelo MJ
    J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjuvant immunotherapy in melanoma: a new approach.
    Elias EG; Tomazic VJ; Buda BS
    J Surg Oncol; 1992 Jul; 50(3):144-8. PubMed ID: 1619935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple cutaneous malignant melanomas with features of primary melanoma.
    Unger SW; Wanebo HJ; Cooper PH
    Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease.
    Gross NJ; Eddie-Quartey AC
    Cancer; 1976 May; 37(5):2183-93. PubMed ID: 769946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intralesional Bacillus Calmette-Guérin immunotherapy of canine venereal tumors.
    Hess AD; Catchatourian R; Zander AR; Epstein RB
    Cancer Res; 1977 Nov; 37(11):3990-4. PubMed ID: 143344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma.
    Plesnicar S; Rudolf Z
    Cancer; 1982 Sep; 50(6):1100-6. PubMed ID: 7104950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 57. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
    J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
    Mavligit G; Gutterman JU; McBride C; Hersh EM
    Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.